A cortically blind patient with preserved visual imagery

Article

The findings of a case report in Cognitive and Behavioral Neurology may support its authors hypothesis that the primary visual cortex, in which retinal spatial geometry is preserved, is not critical for visual imagery.

The findings of a case report in Cognitive and Behavioral Neurology may support its authors hypothesis that the primary visual cortex, in which retinal spatial geometry is preserved, is not critical for visual imagery.

Find out more…

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Angiogenesis 2025: The global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
Veterinary ophthalmology can foster insights and progress in glaucoma care
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
I. Paul Singh, MD, says artificial intelligence will help glaucoma specialists make decisions
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Charles Wykoff, MD, PhD, presents on diabetic retinopathy and "the dream of reperfusion" at Floretina ICOOR 2024
How a gene-agnostic approach opens doors to new therapeutics
How a gene-agnostic approach opens doors to new therapeutics
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
AAO 2024: Main takeaways from the Zoster Eye Disease study
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
AAO 2024: New data illuminate glaucoma care paradigms for surgical interventions
AAO 2024: Chloroprocaine ophthalmic gel as anesthesia for intravitreal injections
AAO 2024: Chloroprocaine ophthalmic gel as anesthesia for intravitreal injections
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
AAO 2024: An oral anaesthetic offers relief for both patients and care teams
AAO 2024: Therapies offering hope for patients diagnosed with TED
AAO 2024: Therapies offering hope for patients diagnosed with TED
Related Content
A flip-calendar shows March 31st as the date, while the United States Food and Drug Administration and European Medicines Agency logos hover above. Image credit: ©Jenn Miranda, via Canva. FDA and EMA logos courtesy respective agencies.

Retina recap: EMA and US FDA approvals, March 2025

Sydney M Crago
April 3rd 2025
Article

Regulatory agencies issued approvals for new treatments and expanded uses of existing therapies in the retina space

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD
July 22nd 2024
Podcast
An image of a person pressing a computer shutdown button, superimposed digitally over the image. Concept for clinical trial discontinuation. Image credit: ©natali_mis – stock.adobe.com

Opthea discontinues COAST and ShORe sozinibercept combination therapy trials

Martin David Harp
April 2nd 2025
Article

Both trials failed to meet their primary endpoints for treatment of age-related macular degeneration

A woman with myopia holds a pair of glasses at a distance and looks through the vision-correcting lens. Paediatric myopia control concept. Image credit: ©Chanintorn.v – stock.adobe.com

French OPHTAMYOP study reveals trends in myopia control

Dominique Bremond-Gignac, MD, PhD, FEBO
April 2nd 2025
Article

How studies into myopia management can increase access to vision care

An image of the European Medicines Agency (EMA) headquarters to accompany a CHMP opinion. Image credit: ©Lubo Ivanko – stock.adobe.com

EMA grants positive CHMP opinion for low-dose atropine SYD-101 (Ryjunea, Sydnexis)

Hattie Hayes
April 1st 2025
Article

A pivotal phase 3 clinical trial found that SYD-101 met its 3-year primary endpoint for slowing paediatric myopia progression

A close-up of a doctor's face. The doctor wears PPE including a mask and safety goggles. Oncology and ophthalmology concept image. Image credit: ©H_Ko – stock.adobe.com

New study investigates ocular involvement in multiple myeloma

Lynda Charters
April 1st 2025
Article

Hematologists and ophthalmologists could work together for earlier diagnoses, research findings indicate

© 2025 MJH Life Sciences

All rights reserved.